Abstract
We studied thrombophilic genetic factors (TGFs) MTHFR C677TT, PAI1 4G-4G, V Leiden Q506, prothrombin G20210A as risk factors in 94 patients with HCC with and without portal vein thrombosis (PVT), compared with 214 patients with liver cirrhosis (LC) with and without PVT and 94 healthy controls (HC). The OR (95% CI) for MTHFR C677TT with HCC was 3.85 (1.55–7.39) vs. HC. The OR for PAI1 4G-4G in HCC, was 2.87 (1.27–6.55) vs. HC. Also prothrombin G20210A was significantly more frequent among HCC, mainly in patients with PVT, while V Leiden factor was equally distributed among HCC and HC. Differences were more significant in patients with associated PVT. These findings suggest that frequently TGFs are needed for patients to be at risk of HCC and PVT. We conclude that in all patients with chronic liver disease TGF screening should be performed to individuate patients at risk of HCC and PVT.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Amitrano L, Brancaccio V, Guardascione MA et al (2000) Inherited coagulation disorders in cirrhotic patients with portal vein thrombosis. Hepatology 31:345–348
Mu LN, Cao W, Zhang ZF et al (2007) Methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C polymorphisms and the risk of primary hepatocellular carcinoma (HCC) in a Chinese population. Cancer Causes Control 18:665–675
Yuan JM, Lu SC, Van Den Berg D et al (2007) Genetic polymorphisms in the methylenetetrahydrofolate reductase and thymidylatesynthase genes and risk of hepatocellular carcinoma. Hepatology 46:749–752
Italian Association for the Study of the Liver (2001) Hepatocellular carcinoma: guidelines for diagnosis and therapy. www.webaisf.org
Pasta L, Marrone C, D’amico M (2005) MTHFR C677T mutations in liver cirrhosis with and without portal vein thrombosis. Liver Int 25:49–5
Tsantes E, Nikolopoulos GK, Bagos PG et al (2007) Association between the plasminogen activator inhibitor-1 4G/5G polymorphism and venous thrombosis. A meta-analysis. Thromb Haemost 97:907–913
Ray JG, Shmorgun D, Chan WS (2002) Common C677T polymorphism of the methylenetetrahydrofolate reductase gene and the risk of venous thromboembolism: meta-analysis of 31 studies. Pathophysiol Haemost Thromb 32:51–58
Marchiori A, Mosena L, Prins MH et al (2007) The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies. Haematologica 92:1107–1114
Soria JM, Almasy L, Souto JC et al (2000) Linkage analysis demonstrates that the prothrombin G20210A mutation jointly influences plasma prothrombin levels and risk of thrombosis. Blood 95:2780–2785
Balta G, Altay C, Gurgey A (2002) PAI-1 gene 4G/5G genotype: a risk factor for thrombosis in vessel of internal organs. Am J Hematol 71:89–93
Decousus H, Moulin N, Quenet S et al (2007) Thrombophilia and risk of venous thrombosis in patients with cancer. Thromb Res 120:51–61
Eroglu A, Ulu A, Cam R et al (2007) Factor V 1691 G-A (Leiden) and prothrombin G20210A polymorphisms and the risk of venous thrombosis among cancer patients. J Thromb Thrombolysis 23:31–34
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
D’Amico, M., Pasta, L. & Sammarco, P. MTHFR C677TT, PAI1 4G-4G, V Leiden Q506, and prothrombin G20210A in hepatocellular carcinoma with and without portal vein thrombosis. J Thromb Thrombolysis 28, 70–73 (2009). https://doi.org/10.1007/s11239-008-0246-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11239-008-0246-6